The most common treatment-related adverse events were leukopenia (61.1%), neutropenia (52.8%), fatigue (50.0%), numbness (44.4%), AST elevation (30.6%) and ALT elevation (27.8%). The gene discussed is GPT; the disease is neutropenia.